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Abstract 
Ovalbumin (OVA) is a protein antigen that is widely used for eliciting cellular and 
humoral immune responses in cancer immunotherapy. As an alternative to solute 
OVA, we have developed an engineering approach towards protein nanoparticles 
(pNPs) based on reactive electrospraying. The resulting pNPs are comprised of 
polymerized OVA, where individual OVA molecules are chemically linked via 
poly(ethylene glycol) (PEG) units. Controlling the PEG/OVA ratio allowed for fine-
tuning of critical physical properties, such as particle size, elasticity, and, at the 
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molecular level, mesh size. As the PEG/OVA ratio decreased, OVA pNPs were more 
effectively processed by dendritic cells, ultimately increasing their ability to stimulate 
the proliferation of OT-I CD8+ cells in vitro. Moreover, pNPs with lower PEG/OVA 
ratios elicited enhanced lymphatic drainage in vivo and increased uptake by lymph 
node macrophages, dendritic cells, and B cells. In addition, pNPs with lower 
PEG/OVA ratios resulted in higher anti-OVA antibody titers in vivo, suggesting 
improved humoral immune responses. While no statistically significant difference 
was observed between 200 and 500 nm pNPs in the in vitro studies, OVA pNPs with 
an average diameter of 500 nm showed significantly higher tissue persistence and 
lower lymphatic drainage than smaller pNPs in vivo. Importantly, OVA pNPs resulted 
in significantly increased median survival relative to solute OVA antigen in a mouse 
model of B16F10-OVA melanoma. Our studies demonstrate that precisely 
engineered OVA pNPs can improve the overall anti-tumor response compared to 
free antigen. The PEG/OVA ratio, along with nanoparticle size, appears to play a 
pivotal role in pNPs’ ability to promote cross-presentation by dendritic cells (cellular 












In cancer immunotherapy, eliciting potent and specific immune responses against 
advanced tumors remains a major challenge.[1] Peptide-based cancer vaccines 
(subunit vaccines) have been extensively studied in the past, because they have 
significant advantages (such as safety and ease of manufacturing) over attenuated, 
inactivated, or biosynthetic vaccines.[2]  However, their efficacy in clinical trials has 
been disappointing, mostly due to inefficient delivery of antigen and adjuvants to 
draining lymph nodes, resulting in immune tolerance and cytotoxic T lymphocyte 
fratricide[3]. On the other hand, high levels of vaccine have been linked to T cell 
sequestration at the vaccination site, resulting in systemic T cell exhaustion and 
deletion[4]. Nanoparticles have been utilized to enhance the therapeutic outcome of 
cancer immunotherapies in the context of subunit antiges, dendritic cell-based 
vaccines, immune checkpoint inhibitors/blockade, adoptive T-cell therapy[5] and 
immunoenhancing agents for in situ vaccination[6]. Cancer vaccine strategies that 
aims to improve early steps of antigen delivery and processing can be also beneficial 
to patients who lack the sufficient pre-existing anti-tumor T cells.[5] Nanoparticle-
based delivery platforms hold the potential to improve vaccine immunogenicity[7] due to 
increased antigen stability, sustained release, site-specific delivery, and improved 
circulation and biodistribution of the antigens[1],[8],[9]. Parameters such as nanoparticle 
size[10], shape[11], charge[12], and administration route[13] are known to affect the immune 
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response, but the mechanism behind cross-presentation and cross-priming of CD8+ 
T cells remains an active area of research.[14] Typically, antigens have been either 
encapsulated in the bulk of nanoparticles for subsequent release or were presented 
on the surface of nanoparticles. Polymer nanoparticles made of natural or synthetic 
polymers, such as chitosan or poly(lactic-co-glycolic acid) (PLGA), have been extensively 
studied for vaccine encapsulation[15],[16],[7l]. Other examples of antigen-encapsulating 
nanomaterials include lipid nanocapsules[7f], [7h], polyelectrolyte capsules 
comprised of peptide antigens and adjuvants made by the layer-by-layer 
technique[7m], or nanoparticles comprised of antigen or adjuvant molecules linked 
to lipophilic albumin-binding tails[7k]. In contrast, antigen conjugation to the surface 
of nanoparticles[17] has been suggested to be superior compared to antigen 
encapsulation for two main reasons: Firstly, the nanoparticles themselves were found 
to trigger inflammatory immune responses when encountered by antigen-presenting cells 
(APCs)[18]. Secondly, antigens presented on the nanoparticle surface can more 
effectively interact with surface receptors of APCs, which appears to enhance crosstalk 
between the innate and adaptive immune system[19]. As an alternative,  virus-like 
particles (VLPs) or protein nanoparticles (pNPs) have been pursued in some instances[7b, 
20]. VLPs are biomimetic engineered particles, which mirror viruses in their structural 
properties. The main concern of VLPs is the risk of inducing anti-carrier antibody 
production. This could potentially limit their clinical translation, because repeated dosing 
could lead to neutralization or reactive toxicities in patients.[21] In addition, off-target 
immune response can be caused by the competition between the carrier antigen and the 
target antigen.[22] Using pNPs comprised of the actual antigen as the main structural unit 
eliminates the need for a separate nanoparticle carrier[23]. If the entire particle, or its 
majority, is comprised of antigen, pNPs have the potential for enhancing DC surface 
receptor engagement, prolonging tissue persistence, sustaining antigen activity and 
minimizing off-target material delivery.[22] In the past, proteins have been assembled into 
particles through structurally ordered assembly, unstructured hydrophobic assembly and 
electrostatic assembly.[22] However, these protein assemblies driven by fusion and 
sequence modification are more likely affected by antigenic variability and the loss of 
their capacity to self-assemble and preserve antigen recognition.[22] Compared to fusion 
and sequence modification, chemical conjugation to proteins, lipids or polymers, 
promises versatility and broader applicability to a wider spectrum of antigens, but 
requires multiple processing steps.[22] For example, crosslinked peptide nanoclusters 
were fabricated for delivery of oncofetal antigen by desolvation and were stabilized 
through disulfide bonds.[23f] However, changes to the primary structure of the protein, 
such as addition of cysteine to the C-terminus of the peptide, was necessary to ensure 
successful crosslinking.  
Another method of nanoparticle fabrication is electrospraying, which involves liquid 
atomization through electrical forces.[24] Electrospraying has been employed in 
biomedical research for fabrication of different types of nanoparticles based on 
natural materials, such as elastin-like polypeptide nanoparticles[25] or insulin 
particles.[26] Electrospraying is a one-step process, which can be applied to a range 
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of proteins and protein mixtures without significantly increasing the engineering 
effort.[24] Another potential advantage of electrospraying is its proven scalability, 
which makes it a valuable method of particle fabrication in industrial applications.[27]  
In electrospraying, the liquid is transported through a metal capillary, which is 
connected to a conductive substrate. The characteristic Taylor cone is formed at the 
tip of the capillary after applying high voltage; nanoparticles are formed after 
evaporation of the solvent and collected on a conductive substrate[24].  
Here, we report a novel synthetic route towards pNPs comprised of polymerized 
ovalbumin (OVA) linked by poly(ethylene glycol) (PEG) units based on reactive 
electrospraying. This scalable particle fabrication technique limits denaturation of 
proteins as confirmed by circular dichroism spectroscopy.[28] Reactive 
electrospraying can be extended to fabricate bicomparmental protein 
nanoparticles[29]; therefore, fabrication of multicompartmental nanoparticles where 
each compartment is made of a different antigen can be feasible with this method 
which is hard-to-achieve otherwise. Conceptually, this approach has the potential to 
reduce competing anti-carrier responses, because the target antigen becomes the 
actual structural building block in pNPs. This novel type of pNPs ensures presentation 
of dense arrays of antigen that should be readily recognizable by APCs. In pNPs 
comprised of polymerized OVA, antigen presentation is critically influenced by the 
crosslinker:protein ratio. Specifically, we have evaluated four types of polymerized OVA 
pNPs with various PEG: OVA ratios in terms of their uptake by dendritic cells, T cell 
activation, lymphatic drainage, antibody production, and anti-tumor efficacy.  
 
Materials and Methods 
Reagents. Ovalbumin (OVA), O, O′-bis[2-(N-succinimidyl-succinylamino)ethyl] 
polyethylene glycol (NHS-PEG-NHS) with a molecular weight of 2000 Da, ethylene 
glycol, 4,6-diamidino-2-phenylindole dihydrochloride (DAPI), carboxyfluorescein 
diacetate N-succinimidyl ester (CFSE), Triton-X 100, and tween 20 were used as 
purchased from Sigma Aldrich, USA. O,O′-bis[2-(N-succinimidyl-
succinylamino)ethyl]polyethylene glycol (NHS-PEG-NHS) with a molecular weight of 
20,000 Da was purchased from Nanocs Inc., USA. BCA assay, endotoxin removal 
spin columns, methanol-free formaldehyde, Alexa Flour™ 488 phalloidin, Alexa 
Fluor™ 647 conjugated albumin from bovine serum (BSA), ProLong™ Gold Antifade 
Mountant, and 96-well flat bottom immunoplates were purchased from ThermoFisher 
Scientific, USA. Endotoxin free water was obtained from G- Biosciences, USA. 
Endotoxin-Free Dulbecco’s PBS was purchased from EMD Millipore, USA. RPMI 
1640 media, fetal bovine serum (FBS), penicillin–streptomycin, b-mercaptoethanol, 
and ACK lysis buffer were obtained from Life Technologies. Granulocyte 
macrophage-colony-stimulating factor (GM-CSF) was the product of PeproTech, 
USA. PE/Cy7 anti-mouse CD11c antibody was purchased from Biolegend, USA. 
Anti-mouse CD8 antibody (CD8-APC) was purchased from BD Biosciences, USA. 
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EasySep™ Mouse CD8+ T Cell Isolation Kit was purchased from STEMCELL 
Technologies, Canada. Biotinylated Rabbit/goat anti-mouse IgG was purchased from 
Southern Biotech, USA.  Streptavidin-HRP was purchased from R&D Systems, USA. 
3,3',5,5'-Tetramethylbenzidine (TMB) substrate was purchased from Surmodics, 
USA. 
Fabrication of OVA pNPs. Ovalbumin nanoparticles (OVA pNPs) were prepared 
using electrospraying. Prior to pNP fabrication, endotoxin-free OVA was prepared 
using spin columns according to manufacturer’s instructions. Protein solutions 
were prepared by dissolving endotoxin-free ovalbumin (7.5 w/v%) and the desired 
amount of NHS-PEG-NHS crosslinker (5, 10, 30 or 50 w/w%) in mixtures of 
endotoxin-free water and ethylene glycol. We used water-to-ethylene glycol ratios 
of 80:20 vol% or 40:60 vol% depending on the formulation. OVA/PEG solutions 
were pumped at a flow rate of 0.1 mL/h. After a droplet has been formed at the 
outlet of the needle, an electric field is applied which results in formation of the 
characteristic Taylor cone. After application of ~10-12kV of voltage, OVA pNPs are 
electrosprayed onto a collector sheet (the distance between the needle tip and the 
collector sheet was adjusted to 20 cm). Afterwards, the pNPs were kept at 37 °C 
for 7 days to complete the crosslinking reaction before being collected in PBS 
buffer containing 0.01% Tween20. Serial centrifugation was employed to separate 
the desired nanoparticles from larger particles (see supporting information for 
detailed centrifugation protocol). Lastly, OVA pNPs were re-dispersed in PBS 
buffer and stored at 4 °C until further use. The concentration of pNPs was 
assessed using bicinchoninic acid (BCA) assay according to manufacturer’s 
instructions. 
 
Characterization of PNPs 
Scanning electron microscopy (SEM). SEM images were recorded using a FEI 
Nova 200 Nanolab SEM/FIB at the Michigan Center for Materials Engineering at 
acceleration voltages of 5kV. Images were processed using ImageJ (Wayne 
Rasband, NIH) to obtain the respective nanoparticle size distribution. For particle 
size determination, >500 particles/sample were measured using ImageJ. 
Dynamic/electrophoretic light scattering (DLS/ELS). DLS/ELS measurements 
were carried out using a Zetasizer Nano ZS (Malvern Panalytical). DLS was 
employed to measure the particle size distribution in PBS buffer after particle 
collection. ELS was employed to determine the zeta potential of OVA NPs. 3 
individual measurements were carried out per sample and averaged to determine 
the particle size and zeta potential.  
Atomic force microscopy (AFM). AFM measurements were carried out using an 
MFP-3D (Oxford Instruments, UK) using CSC-38noAl-A cantilevers (Micromash, 
USA) with a spring constant of 0.09 N/m. Samples were prepared by electrospraying 
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OVA pNPs directly onto silicon substrates coated with poly(4-Penta fluorocphenyl-p-
xylylene) via chemical vapor deposition (CVD) polymerization (see supporting 
information); the substrates were allowed to crosslink at 37 °C for several days prior 
to use. OVA NPs were localized by scanning the surface in tapping mode over a (5 x 
5) m2 area and then decreasing the scan area for visualization of a single NP. The 
force curves were obtained by indenting the tip into the center of an individual 
nanoparticle and recording the deflection of the cantilever.  
Small angle neutron scattering (SANS). SANS experiments were carried out at the 
NIST Center for Neutron Research using the NGB30 instrument. Using neutron 
wavelength of λ = 6 Å and Δλ/λ=0.11 at detector distances 1.3 m, 4.0 m, and 13.2 m, 
we provided a q-range of 0.003 Å-1 to 0.5 Å-1. OVA pNPs with PEG/OVA ratio of 10% 
and 40% dispersed in D2O (2 mg/mL) were loaded into 1 mm titanium scattering 
cells between mounted quartz windows, and a Julabo temperature-controlled bath 
was used to maintain the sample temperature at 37 ˚C. SANS data were then 
collected and reduced using the NCNR IGOR software.[30] Data analysis was 
performed subsequently using the Sasview software.   
 
Preparation of bone marrow-derived dendritic cells (BMDCs). BMDCs were 
prepared according to literature protocols.[31] C57BL/6 mice were kept in a pathogen-
free environment and allowed to acclimate for at least one week before experiments. 
All animal experiments described in this protocol were compliant with the Committee 
on Use and Care of Animals (UCUCA) at the University of Michigan and performed 
according to the established policies and guidelines. Briefly, femur and tibia were 
harvested from C57BL/6 mice. Bone marrow was flushed with a syringe and 
collected. The cell suspension was passed through a 40    cell strainer. After 
centrifugation, cells were plated into non-tissue culture treated Petri-dishes at a 
concentration of 2 million cells per dish in DC media (RPMI 1640 supplemented with 
10% FBS, 1% penicillin-streptomycin, 50     -mercaptoethanol and 20 ng/ml GM-
CSF) at 37 °C with 5% CO2. The media was refreshed on days 3, 6, and 8. BMDCs 
were used for experiments on days 10-12.  
OVA pNP uptake by BMDCs. Internalization of fluorescent OVA pNPs by BMDCs 
was visualized using confocal microscopy and quantified using flow cytometry. 
Fluorescent OVA pNPs were obtained by addition of AlexaFluor 647-conjugated 
albumin from bovine serum (BSA) at 1 mg/ml to the solvent mixture for 
electrospraying of the nanoparticles. For confocal imaging, BMDCs were seeded on 
chamber slides (105 cells/well) and maintained in a humidified incubator at 37°C and 
5% CO2. Cells were incubated with 10  g/ml of OVA NPs for 24 hours. The cells 
were then washed three times with PBS, fixed with 4% paraformaldehyde, washed, 
and permeabilized with 0.1% Triton-X solution which was followed by treatment with 
blocking solution of 1% BSA. The actin filaments were stained with AlexaFluor 488-
Phalloidin and the nucleus was stained with DAPI. The samples were imaged using 
a 63x oil-immersion lens on a Nikon A-1 spectral confocal microscope located at the 
Microscopy and Image Analysis Laboratory (MIL) at the University of Michigan.  
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Flow cytometry was used for quantitative uptake studies. BMDCs were plated in a 
12-well plate at a density of 1 million cells per well in DC media. After 24 hours, 
media was removed from the wells to remove non-adherent cells, and fresh media 
containing different nanoparticle groups at 10  g/ml was added to the wells. After 24-
hour incubation of cells with OVA nanoparticles, the cells were washed with PBS 
three times and then trypsinized. The cells were washed two more times and stained 
with CD11c-PE/Cy7 and DAPI before analyzing them via flow cytometry using a 
Cytoflex (Beckman Coulter) cell analyzer located at the Flow Cytometry Core of the 
University of Michigan. Data were analyzed using FlowJo software.  
 
CFSE dilution assay. CFSE dilution assay was performed to evaluate the 
proliferation of OT-I CD8+ cells after co-culture with OVA pNP-treated BMDCs. 
BMDCs were seeded in 96-well plates at a density of 50,000 cells/well and then 
incubated with the respective OVA NPs groups, soluble OVA, SIINFEKL (positive 
control), and PBS (negative control) overnight. Naive CD8+ T cells were isolated 
from the spleen of OT-I transgenic mice using a magnetic CD8+ T-cell-negative 
selection kit. OT-I CD8+ cells were fluorescently labeled by incubation with CFSE (1 
 M) for 10 min at 37°C. CFSE-labeled OT-I CD8+ T cells were then co-cultured with 
OVA pNP-treated BMDCs in 96 well plates at a density of 50,000 cells/well for 72 
hours. BMDCs were washed with PBS three times before co-culture. Cells were then 
stained with CD8 -APC and DAPI, and flow cytometry (Cytoflex, Beckman Coulter) 
was used to determine the percentage of live, proliferated OT-I CD8+ cells. The data 
was processed using FlowJo software and reported as % CFSE dilution, which is 
proportional to OT-I CD8+ cell proliferation. 
Immunization. Six-week-old, female C57BL/6 mice were purchased from Jackson 
Laboratory. Mice (n=5 per group) were immunized subcutaneously at the tail base at 
a dose of 10  g OVA with 15  g CpG in 100  l sterile PBS buffer (primary 
immunization). Boost immunization was performed on day 21 after primary 
immunization. On days 20 and 42, blood was collected by submandibular bleed for 
serum antibody titers analysis. To separate serum, the collected blood was 
centrifuged at 10,000 x g for 5 mins. Serum was then stored at -80°C until analysis. 
ELISA. For ELISA analysis, 96 well flat bottom Immunoplates (Thermo Scientific) 
were coated with 1  g/well OVA solution in 0.05 M carbonate-bicarbonate buffer (pH 
9.6) and incubated overnight at 4°C. Plates were then washed with 50 mM Tris, 0.14 
M NaCl, 10.05% Tween 20 (pH 8) followed by blocking with 50 mM Tris, 0.14 M 
NaCl, 1% BSA (pH 8) for 1 hour at room temperature. Samples were diluted in 50 
mM Tris, 0.14 M NaCl, 0.05% Tween 20, 1% BSA and added to each well for an 
hour incubation at room temperature. After washing, the plates were incubated with 
diluted horseradish peroxidase enzyme (HRP) conjugated Rabbit anti-mouse IgG for 
an hour. The plates were then washed and incubated with TMB substrate solution for 
10 minutes. The reaction was stopped by addition of 2 M H2SO4 solution. The plates 
were read at the wavelength of 450 nm using a plate reader.  
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Statistical analysis. All quantitative experiments were performed in triplicate and 
are presented as arithmetic mean ± SEM. Statistical analysis were performed using 
SPSS Statistics 24 software. One-way ANOVA with Tukey’s post-test was used to 
determine significance among groups. A P-value of  0.05 was considered 
statistically significant (*P 0.05, **P 0.01, ***P 0.001; ****P<0.0001); P-values of 
 0.05 were considered not significant (ns). 
 
Results and Discussion 
Preparation of OVA pNPs. OVA pNPs were prepared using reactive 
electrospraying, as shown in Figure 1A. To synthesize OVA pNPs, OVA was 
dissolved in water/ethylene glycol (7.5 w/v%). The OVA solution was mixed with the 
amine-reactive crosslinker NHS-PEG-NHS at variable ratios. During reactive 
electrospraying, we employed a solvent mixture comprised of water and ethylene 
glycol (80:20 vol%) and used NHS-PEG-NHS with molecular weight of 2kDa. Under 
these conditions, the PEG units form amide-bonds with amino groups in the antigen, 
such as OVA’s lysine residues, resulting in stable, polymerized OVA pNPs. To 
ensure completion of the reaction, OVA pNPs were stored at 37 °C for 7 days prior 
to collection. To adjust the network structure of OVA pNPs, we varied the PEG/OVA 
ratio as follows: 10% to 30% and 50% (w/w%). Electrospraying resulted in pNPs of 
200-300 nm in their fully hydrated state (Figure 1F). We found parameters, such as 
protein concentration, solvent viscosity and solvent dielectric constant, can be 
adjusted to control the size and network structure in pNPs. To increase the size of 
hydrated OVA pNPs to 500 nm, the ratio of water-to-ethylene glycol was decreased 
to 40:60 (vol%), which effectively decreases the overall dielectric constant of the 
solvent system and increases nanoparticle size.[32]  However, additional optimization 
was required to obtain 500 nm OVA pNPs. First, the PEG/OVA ratio was decreased 
to 5% (w/w). Second, the molecular weight of the PEG crosslinker was increased 
from 2 kDa to 20 kDa. Through these modifications, we were able to reliably prepare 
hydrated OVA pNPs with size of 500 nm, as confirmed by dynamic light scattering. 
Figure 1B-E show SEM images of the different OVA pNPs as collected on the 
counter electrode. The pNPs were dispersed in PBS buffer, and their zeta potential 
and size were measured using ELS and DLS. The zeta potentials among four types 
of OVA pNPs were not statistically significant different (see supporting information, 
Table S3). The stability of OVA pNPs was confirmed using DLS measurements over 
a time period of 36 days. (see supporting information, Figure S2). 
 The size of hydrated nanoparticles characteristically increased with lower PEG/OVA 
ratio (Figure 1F). The swelling of the particles with respect to their SEM dry size was 
estimated using[33]: 
                
         
    
 (Equation 1) 
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where dDLS and dSEM are the nanoparticle diameters obtained from DLS and SEM 
(see supporting information, Table S1 for DLS and SEM size data) that were used to 
calculate VSwollen and Vdry , respectively, assuming a spherical geometry for 
nanoparticles.  
OVA pNPs with PEG/OVA ratios of 5, 10, 30 and 50% showed swelling ratios of 
24.7, 29, 13.3 and 9.4, respectively. These differences in the swelling behavior 
suggest substantial differences in the mesh sizes of the protein gels that the pNPs 
are comprised of. The dependency of pNP swelling on crosslinker amount indicates 
that our reactive electrospraying procedure, in fact, does yield particles with different 
mesh size. However, we aimed at quantifying the mesh size more accurately using 
small-angle neutron scattering to evaluate the network density of polymerized pNPs. 
Mesh size of OVA pNPs. We conducted SANS measurements of two 
representative OVA pNPs, 10% and 50% PEG/OVA NPs dispersed in D2O (2 
mg/mL). We expected that the scattering from the hydrated protein network 
resembles the scattering from heterogeneous synthetic polymer hydrogels,[34] which 
can be modeled as a disordered two-phase system with a protein-rich network phase 
and a protein-poor polymer phase. Accordingly, the scattering curves were fitted to a 
combined Porod model[35] and the Debye-Anderson-Brumberger (DAB) model[36] 
(solid black lines in Figure 1H) according to 
 
 ( )   
   (   )(  )   




  (Equation 2) 
 
where A is a coefficient that determines the relative magnitude of Porod scattering. 
The DAB model (first term in equation (2)) describes scattering from the 
concentration correlations between the protein-rich phase with volume fraction   and 
scattering length density contrast    with the surrounding fluid that is randomly 
distributed into domains of average spacing  . The Porod model (second term in 
equation (2)) represents scattering from smooth interfaces between the protein-rich 
and protein-poor domains. 
 
Equation (2) provides fits of the observed SANS spectra from the two samples. At 
low q-values, we observe a q-4 dependence of the scattering data, consistent with 
scattering from a smooth interface. At moderate q-values, the length scale ξ is 
apparent as a shoulder in the scattering curve. It can be noted that the overall fit for 
50% PEG/OVA pnPs is poor in the region where the Porod and the DAB model 
contributions are of similar magnitude (q~0.01-0.02 Å-1). The explanation for this lies 
in the interference between the Porod scattering from the interfaces of the protein-
rich domains and the DAB scattering from polymer chains inside the domains. This is 
not accounted for in the model and would likely show up in the mid q-range, where 
the model gives a poor fit.  
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We found that the DAB scale factor (   (   )(  ) ) increases four-fold as the 
PEG/OVA ratio increased from 10% to 50%, confirming the densification of the 
protein network as the degree of crosslinking increases. Furthermore, ξ decreased 
nearly two-fold as the PEG/OVA ratio increased from 10% to 50% (Table 1), thus 
revealing a more finely divided structure with increasing PEG/OVA ratio. Together, 
these results suggest that the protein network becomes denser and more finely 
heterogeneous with increasing PEG/OVA ratio, consistent with a more porous but 




Table 1. Fit parameters from DAB model. 
  10 % PEG/OVA 50% PEG/OVA 
Porod scale factor, A 3.70  10
-9 
+ 2.99  10
-13
 5.92  10
-9 
+ 1.02  10
-13 
DAB scale factor,    (   )(  )    4.92  10
-6 




+ 1.60  10
-7 
Correlation length,   (nm) 3.98 + 0.12 2.15 + 0.01 
 
 
Elasticity of OVA pNPs. Since the ability for the uptake of pNPs by cells might be 
affected by the mechanical properties of the pNPs, we measured the elastic moduli 
of the OVA pNPs. We conducted AFM indentation measurements to obtain the 
elastic moduli for polymerized OVA pNPs (Figure 1I; see supporting information for 
force-indentation profiles, Figure S1). All AFM force measurements were conducted 
at 37 °C to mimic cellular uptake experimental conditions. Elastic (E) moduli were 
extracted from the experimental force-indentation profiles by fitting the profiles using 
the Hertz model for a conical indenter according to  
   
       
  (    )
    (Equation 3)
where F is the indentation force,   is the indentation,  is the half-opening angle of 
the indenter, E is the E modulus of the NPs, and v is the Poisson ratio of the NPs.[37] 
A value of v = 0.5 was used to fit the profiles using equation (3).[38] The Hertz model 
assumes that the nanoparticles exhibit a uniform E modulus. It can be applied even 
for heterogeneous nanoparticles such as our OVA pNPs, as the length scale over 
which the probe deforms the pNPs is large relative to the size of the density 
heterogeneities. Our results show that the E modulus increases with increasing 
PEG/OVA ratio. This dependency of crosslinker density and E modulus has been 
previously observed[39] and was associated with increasing stiffness of the OVA 
pNPs with increasing PEG/OVA ratio. In our study, the increase in E modulus was 
directly correlated to the increase in PEG/OVA ratio, as expected for rubber-like 
materials such as polymer hydrogels[40]. The increase in stiffness coincides well with 
the decrease in correlation length from SANS (Table 1) and the decrease in swelling 
ability (Figure 1G).  
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Cellular uptake of OVA pNPs. The uptake of engineered OVA pNPs by BMDCs 
was evaluated quantitively by flow cytometry (Figure 2A) and further visualized by 
confocal microscopy (Figure 2B-E) using AlexaFluor 647-labeled OVA pNPs. The 
fluorescence intensity of OVA NPs (10  g/ml) was quantified using a plate reader; 
we found no significant differences in fluorescence intensity between the different 
nanoparticle groups (see supporting information, Table S2). To investigate the 
interaction between OVA pNPs and BMDCs, confocal microscopy was used. BMDCs 
were incubated with AlexaFluor 647-labeled OVA pNPS with different PEG/OVA 
ratio for 24h at 37 . The actin filaments were stained with AlexaFluor 488-Phalloidin 
and the nucleus was stained with DAPI. As shown in Figure 2B-E, OVA pNPs of 
different PEG/OVA ratio were successfully internalized  by BMDCs allowing for 
intracellular antigen delivery to BMDCs. As seen in the confocal images, pNPs with 
higher PEG/OVA ratio showed reduced uptake. To quantify the uptake of OVA pNPs 
by BMDCs, flow cytometry was used. OVA pNPs were incubated with BMDCs for 
24h at a concentration of 10  g/ml. Cellular uptake was quantified using flow 
cytometry by comparing the mean fluorescence intensity (MFI) values (see 
supporting information, Figure S4-S7). Our data show that there is a difference in the 
MFI values for OVA pNPs with different crosslinking density. MFI values were 
increased for pNPs with lower PEG/OVA ratio (10%), which correlated with higher 
cellular uptake, compared to the other groups. Cells incubated with pNPs with a 10% 
PEG/OVA ratio showed 6.9-fold greater MFI than those exposed to pNPs comprised 
of 50% PEG/OVA (P < 0.0001). However, MFI values for cells incubated with pNPs 
with 5% and 10% PEG/OVA ratios were not statistically different (P > 0.05). It has 
been shown previously that the elasticity of nanoparticles affected cellular uptake: 
Nanoparticles with Young’s moduli between 30 and 140 kPa showed the highest 
uptake by RAW 264.7 macrophages, while softer (<30 kPa) or harder (>140 kPa) 
NPs showed reduced uptake[41]. In our case, pNPs with PEG/OVA ratios of 5% and 
10%, which had intermediate elasticity as indicated by E moduli of E = 43 kPa, were 
associated with the highest levels of cellular uptake. 
Antigen cross-presentation by OVA pNPs. Eliciting an effective immune response 
requires delivery of OVA to antigen-presenting cells (APCs), such as dendritic cells 
(DCs). DCs digest OVA through a process called cross-presentation, which results in 
the activation and proliferation of CD8+ T cells. Thus, the ability of OVA pNP-treated 
BMDCs to promote antigen cross-presentation and induce antigen-specific 
proliferation of OT-I CD8+ cells were evaluated using a CFSE dilution assay (Figure 
3F, G). CFSE dilution is proportional to the proliferation of OT-I CD8+ cells.  
Therefore, BMDCs were first incubated with OVA pNPs or soluble OVA (control) at 
10  g/mL for 24h. BMDCs were then co-cultured with CFSE-labeled naïve OT-I 
CD8+ T cells, which recognize the OVA-derived epitope SIINFEKL presented in the 
context of MHC-I H2Kb. After 72h of co-culture, the population of proliferated CD8+ T 
cells was assessed using flow cytometry. We found that proliferation was affected by 
the PEG/OVA ratios of the pNPs. The OVA pNPs with PEG/OVA ratio of 5% showed 
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4.4-fold (P < 0.0001) higher proliferation rates than pNPs with a 50% PEG/OVA ratio. 
Similarly, pNPs with PEG/OVA ratio of of 10% and 30% showed 3.6-fold (P < 0.001) 
and 3.1-fold (P < 0.01) higher proliferation rates than pNPs comprised of 50% 
PEG/OVA, respectively. Cross-priming and proliferation of the OT-I CD8+ cells were 
significantly enhanced for OVA pNPs with 5% (P < 0.0001), 10% (P < 0.0001) and 
30% (P < 0.01) PEG/OVA ratios as compared to solute OVA (Figure 3A). While all 
pNP groups outperformed solute OVA, 5% and 10% PEG/OVA pNPs were most 
efficient in promoting antigen cross-presentation and proliferation of OT-I CD8+ cells. 
This result suggests (1) greater uptake of 5% and 10% PEG/OVA pNPs by BMDCs 
and (2) facilitated the processing of OVA pNPs by BMDCs due to lower crosslinking 
density and larger size of 5 and 10% PEG/OVA pNPs. There is some evidence that 
larger particles can direct antigen to the class I antigen presentation pathway more 
efficiently[42], which might explain the higher proliferation values for 5% PEG/OVA 
pNPs (500 nm vs. 200 nm). Once internalized by BMDCs, smaller particles are 
shuttled more rapidly to an acidic environment than larger ones,[14a] which can lead 
to fast and unregulated degradation and inefficient cross-presentation.[14a] Larger 
particles remain longer in a neutral environment, thus preserving the antigens for 
more efficient cross-presentation.[14a] Our results indicate that the PEG/OVA ratio is 
an important parameter for enhancing proliferation of CD8+ T cells, lower PEG/OVA 
ratios resulting in higher proliferation rates.  
Humoral immune responses after subcutaneous delivery of OVA pNPs. Our 
next aim was to investigate the in vivo performance of the pNPs by evaluating their 
ability to induce humoral immune responses in mice. Following the prime-boost 
vaccine regimen shown in Figure 3A, we injected C57BL/6 mice subcutaneously at 
the tail base with OVA pNPs of varying PEG/OVA ratio (10, 30, 50 %) and size (200 
nm, 500 nm) or solute OVA (10  g OVA/100  L dose), co-administered with CpG (15 
 g/dose). Boost immunization was performed on day 21 after primary immunization. 
Anti-OVA serum IgG responses were measured on days 20 and 42 using an ELISA 
assay. Compared to soluble OVA, pNPs with a 10% PEG/OVA ratio elicited 49.4-fold 
increase in anti-OVA serum IgG titers in prime (P < 0.0001) and 9.1-fold increase in 
boost immunization (P < 0.05), respectively. In addition, anti-OVA serum IgG titers 
induced after prime immunization with pNPs of 30% and 50% PEG/OVA ratios 
exhibited 39.9-fold (P < 0.0001) and 26.5-fold (P < 0.01) increase compared to 
soluble OVA, respectively. Among the pNPs groups, 10% PEG/OVA ratio pNPs 
outperformed pNPs comprised of 50% PEG/OVA, as indicated by a 1.9-fold increase 
in anti-OVA serum IgG titers after prime immunization (P < 0.01). Our results show 
that 2 doses of OVA pNPs administered in a prime-boost regimen elicited stronger 
humoral immune responses than the equivalent doses and regimen of soluble OVA 
(Figure 3 B, C). While the larger, 5% PEG/OVA pNPs showed stronger CD8+ T cell 
responses in vitro, the same particles elicited a weaker humoral immune response in 
vivo (comparable to soluble OVA). Because the elasticity of 5 and 10% PEG/OVA 
pNPs was similar, the weaker humoral immune response of 5% PEG/OVA pNPs can 
be attributed to their larger size (500 nm). Larger pNPs may have limited lymphatic 
drainage due to extended tissue persistence at the injection site.  
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OVA pNPs delivery to lymph nodes. Next, we evaluated the pNPs targeting of the 
draining lymph nodes using AlexaFluor 647-labeled pNPs. OVA pNPs of varying 
PEG/OVA ratio (10, 30, 50 %) and size (200 nm, 500 nm) were injected 
subcutaneously at the tail base of C57BL/6 mice (10  g OVA/100  L dose). The 
inguinal draining lymph nodes were harvested 48h after injection. We prepared 
single-cell suspensions from the draining lymph nodes and analyzed pNPs uptake 
among the different populations of antigen-presenting cells (dendritic cells, 
macrophages and B cells) using flow cytometry by comparing the MFI values of the 
cells. We found that the MFI values of F4/80+ macrophages, B220+ B cells and 
CD11c+ DCs (Figure 3D-F) increased with decreasing PEG/OVA ratio for the smaller 
(200 nm) pNPs with 10%, 30% and 50% PEG/OVA ratio. 50% PEG/OVA pNPs did 
not show any significant difference compared to soluble OVA. However, 10% 
PEG/OVA pNPs were delivered more efficiently to F4/80+ macrophages (P < 0.05), 
B220+ B cells (P < 0.01) and CD11c+ DCs (P < 0.005) compared to 50% PEG/OVA 
pNPs. Specifically, the antigen delivery to B220+ B cells by 10% PEG/OVA pNPs, 
even at short time point, was increased compared to 50% (P < 0.01), 5% PEG/OVA 
pNPs (P < 0.01) and soluble OVA (P < 0.05), which correlated well with the trend of 
induction of anti-OVA serum IgG titers measured by ELISA. The MFI values of cells 
with larger (500 nm) 5% PEG/OVA pNPs was significantly lower than 10% PEG/OVA 
pNPs, indicating that the pNPs were not delivered to draining lymph nodes efficiently 
due to their larger size. In the past, many different particle sizes have been studied 
with respect to their lymphatic drainage[10a, 10b, 43],[44],[42],[7e, 45]. It has been shown that 
particles exceeding 500 nm can be trapped at the injection site. Nanoparticles 
smaller than 10 nm, or soluble antigen, diffuse into the lymphatic system easily, but 
their retention time in the lymph nodes is too short to provide sustained antigen 
delivery.[1b] This may explain why OVA pNPs with 500 nm size and soluble OVA 
were not delivered to the lymph nodes efficiently, while we observed improved NP 
uptake by lymph node cells for the smaller OVA pNPs. For smaller pNPs sizes, 
improved uptake was observed for pNP with lower PEG/OVA ratio. 
 
Therapeutic efficacy of pNPs in a model of melanoma. Encouraged by the fact 
that OVA pNPs with 10% PEG/OVA ratio resulted in increased OT-I CD8+ cell 
proliferation in vitro, improved uptake by APCs (both in vitro and in vivo), and 
enhanced humoral immune response in vivo, we employed a murine model of 
B16F10-OVA melanoma to evaluate the therapeutic efficacy of pNPs with a 
PEG/OVA ratio of 10% compared to solute OVA. Tumor-bearing mice were treated 
with 10 % PEG/OVA pNPs or solute OVA (10  g OVA/ 100 L dose), co-
administered with CpG (15  g/dose). Following the regimen shown in Figure 4A, we 
inoculated C57BL/6 mice (10 mice/treatment group) with 1×105 B16F10-OVA cells in 
the SC flank on day 0. Treatments with either 10 % PEG/OVA pNPs or solute OVA 
were initiated on day 7 after tumor inoculation. A second treatment was given on day 
14. Mice were euthanized after their tumors reached 15 mm in any dimension. 
Compared to the no treatment control group, mice treated with solute OVA showed 
slightly better survival. More than 50 % of mice treated with solute OVA were 
euthanized due to large tumor burden on day 20, and 100 % of the mice were 
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euthanized on day 21. In contrast, 100 % of mice treated with 10 % PEG/OVA pNPs 
were alive on day 21 and showed improved survival until the endpoint of the study 
(day 24). Treatment with 10% PEG/OVA pNPs significantly enhanced antigen-
specific CD8+ T cell immune response compared to solute antigen and PBS groups. 
(see supporting information, Figure S3.) 
The survival rate of B16F10-OVA tumor-bearing mice were increased after 
immunization with OVA pNPs compared to solute antigen treatment. The survival 
data observed with OVA pNPs is comparable to previous studies that conducted 




We employed reactive electrospraying, a novel, yet scalable and versatile 
nanoparticle manufacturing process, for development of engineered OVA pNPs with 
defined physico-chemical properties. We identified key parameters (e.g., size or 
PEG/OVA ratio) that determined the immunological responses of pNPs. Specifically, 
lower PEG/OVA ratios resulted in softer pNPs with larger mesh sizes, which, in turn, 
resulted in improved CD8+ T cell activation in vitro and improved lymph node 
drainage and humoral immune response in vivo. Identifying the significance of these 
parameters allowed us to design a pNP formulation with preclinical potential. In a 
preclinical murine model of melanoma, we found that the smaller (200 nm) pNPs of 
10% PEG/OVA ratio resulted in improved survival of mice bearing advanced 
melanoma tumors. In future studies, to improve the clinical relevance, a combination 
strategy using different types of immunotherapies should be employed. In this case, 
a combination of OVA pNP administration with adjuvant therapy and immune 
checkpoint inhibitor therapy could result in further improvement of the preclinical 
outcomes.  
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Figure 1. Preparation and characterization of four types of engineered OVA pNPs via reactive electrospraying: (A.) 
Setup for electrospraying used for preparation of engineered OVA pNPs. SEM images of OVA pNPs with (B.) 5 w/w% 20kDa 
crosslinker, (C.) 10 w/w% 2kDa crosslinker,  (D.) 30 w/w% 2kDa crosslinker, and (E.) 50 w/w% 2kDa crosslinker. (F.) The size 
of hydrated pNPs was measured using DLS after NP collection and dispersion in PBS buffer. (G.) shows a table with 
parameters/conditions for electrospraying of the OVA pNPs. (H.) SANS data and fits for OVA pNPs with 10% and 50% 
PEG/OVA ratio. OVA pNPs were dispersed in D2O at 2 mg/mL. Data were fitted using the Debye-Anderson-Brumberger (DAB) 
model (see main text for more information). (I.) Young’s modulus as a function of the pNP PEG/OVA ratio. Data were obtained 
by fitting the force-distance profiles (see supporting information, Figure S1) obtained from AFM measurements using the Hertz 
model for a conical indenter. 
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Figure 2.  In vitro Cell Uptake of fluorescently labeled OVA pNPs by BMDCs: (A.) Quantitative uptake data (MFI values) 
were obtained by flow cytometry. The data represent the mean ± SEM using triplicates. (B.-E.) Uptake was further visualized by 
confocal microscopy. BMDCs were incubated with OVA pNPs (magenta) at 10 ug/mL for 24h. The actin filaments were stained 
with AlexaFluor 488-Phalloidin (yellow) and the nucleus was stained with DAPI (blue). For flow cytometry, BMDCs were stained 
for DC marker CD11c+ using anti-CD11c+ PE-Cy7; they were also stained with DAPI. For confocal microscopy, actin was 
stained with phalloidin488 and nuclei were stained with DAPI. OVA pNP-treated BMDCs induce proliferation of OT-I CD8+ 
cells: (F.) Percentage of proliferated OT-I CD8+ cells after co-culture with BMDCs incubated with 10 ug/mL OVA pNPs (5% 20k 
XL, 10% 2k XL, 30% 2k XL, 50% 2k XL). The data represent the mean ± SEM from triplicates of three experiments. (G.) 
Representative flow cytometry histograms of (F.). All shown data were analyzed by one-way ANOVA, followed by Tukey’s post-
test. A P-value of  0.05 was considered statistically significant (*P 0.05, **P 0.01, ***P 0.001; ****P<0.0001); P-values of 
 0.05 were considered not significant (ns). 
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Figure 3. Humoral responses elicited by engineered OVA pNPs in immune competent mice: (A.) Vaccine doses and 
regimen. Naïve C57BL/6 mice were injected with OVA pNPs and soluble CpG subcutaneously at the tail base on Day 0 (prime 
immunization) and 21 (boost immunization). Serum anti-OVA IgG titers were measured on (B.) Day 20 (prime response) and 
(C.) Day 28 (boost response). The data were fitted by logarithmic regression. The titer was calculated by solving for the inverse 
dilution factor resulting in an absorbance value of 0.5. Data represent mean ± SEM (n=5). Groups were compared using one-
way ANOVA with Tukey’s post-test. P < 0.05 was considered statistically different (*P < 0.05, **P < 0.01, ***P < 0.001, and 
****P < 0.0001). P > 0.05 was considered not significant. Delivery of pNPs to dLNs: MFI of AlexaFluor 647 associated with OVA 
NPs among (D.) F4/80+ macrophages, (E.) B220+ B cells and (F.) CD11c+ DCs obtained from a single cell suspension from 
draining lymph nodes. Groups were compared using one-way ANOVA with Tukey’s post-test. P < 0.05 was considered 
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Figure 4.  Therapeutic effect of engineered OVA pNPs in melanoma-bearing mice: (A.) Vaccine doses and regimen and 
(B.) animal survival. C57BL/6 mice were inoculated subcutaneously with 1×10
5
 B16F10-OVA cells on day 0. On day 7 and 14, 
mice were treated with indicated formulations (OVA pNP, soluble OVA, PBS) containing 10  g/dose OVA and 15  g/dose CpG 
(L dose). Data represent mean ± SEM (n=10). Groups were compared using Kaplan-Meier estimator analysis. P < 0.05 
was considered statistically different (*P < 0.05, **P < 0.01, and ***P < 0.001). P > 0.05 was considered not significant. 
 
As an alternative to solute model antigen ovalbumin for cancer immunotherapy, a 
novel synthetic route towards protein nanoparticles (pNPs) comprised of polymerized 
ovalbumin linked by poly(ethylene glycol) units is developed based on reactive 
electrospraying. This engineering approach allows fine tuning the physico-chemical 
properties of pNPs such as particle size, elasticity, and, at the molecular level, mesh 
size. These properties are further related to pNPs induced enhanced humoral and 
cellular immune responses and improved anti-tumor efficacy. 
 
 
 
